Pharvaris Announces Positive Top-line Phase 2 Data from the

Primary endpoint met: deucrictibant significantly reduced attack rate The primary endpoint of the CHAPTER-1 study measured the time-normalized number of investigator-confirmed HAE attacks during the treatment period. The monthly attack rate was reduced by 84.5% (p=0.0008) compared to placebo in participants who received 40 mg/day of deucrictibant. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to place

Related Keywords

Switzerland , Berndt Modig , Marca Riedl , Peng Lu , Office Of Pharvaris , Us Hereditary Angioedema Association , Angioedema Center , University Of California San Diego , Clinical Service , Study Design , Clinical Director , Angioedema Association , California San Diego , Clinical Service Chief , Chief Medical Officer , Chief Executive Office , Preventative Treatment , Attack Rate , Prophylaxis , Primary Endpoint , Clinical Study , Treatment Period , Placebo ,